Improving Microvascular Outcomes in Patients with Diabetes through Management of Hypertension

References

• . Cowie CC, Rust KF, Ford ES,. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association and the American College of Cardiology. Make the Link! Initiative. http://www.diabetes.org/heart-disease-stroke.jsp. Accessed December 2008
   Google Scholar
• . Rosenbloom AL. Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatr Drugs. 2002;4(4):209–221
   PubMedGoogle Scholar
• . Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128(5 pt 1):608–615
   PubMed Web of Science ®Google Scholar
• . Laurencin MG, Goldschmidt R, Fisher L. Type 2 diabetes in adolescents. How to recognize and treat this growing problem. Postgrad Med. 2005;118(5):31–36, 43
   PubMed Web of Science ®Google Scholar
• . Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75
   PubMed Web of Science ®Google Scholar
• . Geiss LS, Rolka DB, Engelgau MM. Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med. 2002;22(1):42–48
   PubMed Web of Science ®Google Scholar
• . Milicevic Z, Raz I, Beattie SD,. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care. 2008;31( suppl 2):S155–S160
   PubMedGoogle Scholar
• . Tesfaye S, Chaturvedi N, Eaton SE,; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–350
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Williams M, Dworkin L,. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646–661
   PubMed Web of Science ®Google Scholar
• . Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab. 2007;9(6):781–791
   PubMed Web of Science ®Google Scholar
• . Jonk AM, Houben AJ, de Jongh RT, Serné EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Physiology (Bethesda). 2007;22:252–260
   PubMed Web of Science ®Google Scholar
• . Trevisan R, Vedovato M, Mazzon C,. Concomitance of diabetic retinopathy and proteinuria accelerates the rate of decline of kidney function in type 2 diabetic patients. Diabetes Care. 2002;25(11):2026–2031
   PubMed Web of Science ®Google Scholar
• . Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–3277
   PubMed Web of Science ®Google Scholar
• . MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care. 2004;27(1):195–200
   PubMed Web of Science ®Google Scholar
• . Rigalleau V, Lasseur C, Raffaitin C,. Normoalbuminuric renal insufficient diabetic patients: a lower-risk group. Diabetes Care. 2007;30(8):2034–2039
   PubMed Web of Science ®Google Scholar
• . Bash LD, Selvin E, Steffes M, Coresh J, Astor BC. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2008;168(22):2440–2447
   PubMedGoogle Scholar
• . Fioretto P, Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol. 2007;27(2):195–207
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Nephropathy in Diabetes. Diabetes Care. 2004;27(1):S79–S83
   PubMedGoogle Scholar
• . Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 1995;26(6 pt 1):869–879
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Diabetes Data and Trends. http://apps.nccd.cdc.gov/DDTSTRS/default.aspx. Accessed December 2008
   Google Scholar
• . Davidson JA, Ciulla TA, McGill JB, Kles KA, Anderson PW. How the diabetic eye loses vision. Endocrine. 2007;32(1):107–116
   PubMed Web of Science ®Google Scholar
• . Fong DS, Aiello L, Gardner TW,; American Diabetes Association. Retinopathy in diabetes. Diabetes Care. 2004;27( suppl 1):S84–S87
   PubMed Web of Science ®Google Scholar
• . Wilkinson CP, Ferris FL 3rd, Klein RE,. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677–1682
   PubMed Web of Science ®Google Scholar
• . Pache M, Kube T, Wolf S, Kutschbach P. Do angiographic data support a detailed classification of hypertensive fundus changes? J Hum Hypertens. 2002;16(6):405–410
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761–1769
   PubMed Web of Science ®Google Scholar
• . Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664
   PubMed Web of Science ®Google Scholar
• . Silva KC, Pinto CC, Biswas SK, de Faria JB, de Faria JM. Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by hypertension. Curr Eye Res. 2007;32(6):533–541
   PubMed Web of Science ®Google Scholar
• . Lopes de Faria JM, Silva KC, Boer PA,. A decrease in retinal progenitor cells is associated with early features of diabetic retinopathy in a model that combines diabetes and hypertension. Mol Vis. 2008;14:1680–1691
   PubMed Web of Science ®Google Scholar
• . Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension. 2009;53(2):175–181
   PubMed Web of Science ®Google Scholar
• . Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338(10):645–652
   PubMed Web of Science ®Google Scholar
• . Hansson L, Lindholm LH, Niskanen L,. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611–616
   PubMed Web of Science ®Google Scholar
• . Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care. 2000;23(7):888–892
   PubMed Web of Science ®Google Scholar
• . , Patel A, ADVANCE Collaborative GroupMacMahon S,. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840
   PubMed Web of Science ®Google Scholar
• . Tatti P, Pahor M, Byington RP,. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21(4):597–603
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713
   PubMed Web of Science ®Google Scholar
• . Adler AI, Stratton IM, Neil HA,. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419
   PubMed Web of Science ®Google Scholar
• . Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359(15):1565–1576
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44( suppl 2):S54–S64
   PubMed Web of Science ®Google Scholar
• . Pieske B, Wachter R. Impact of diabetes and hypertension on the heart. Curr Opin Cardiol. 2008;23(4):340–349
   PubMed Web of Science ®Google Scholar
• . Ryden L, Standl E, Bartnik M,; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31( suppl 1):S12–S54
   PubMed Web of Science ®Google Scholar
• . Chobanian AV, Bakris GL, Black HR,; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Cushman WC, Ford CE, Cutler JA,; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404
   PubMedGoogle Scholar
• . Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 2008;10(9):707–713; discussion 714–705
   PubMed Web of Science ®Google Scholar
• . Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 suppl B):9–20
   PubMed Web of Science ®Google Scholar
• . Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens. 2003;16(5 pt 1):407–415
   PubMed Web of Science ®Google Scholar
• . Weber MA, Giles TD. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med. 2006;7(2):45–54
   PubMed Web of Science ®Google Scholar
• . Brown MJ. Aliskiren. Circulation. 2008;118(7):773–784
   PubMed Web of Science ®Google Scholar
• . Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens. 2006;20(2):101–108
   PubMed Web of Science ®Google Scholar
• . Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557): 201–207
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–153
   PubMed Web of Science ®Google Scholar
• . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROSHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253–259
   PubMed Web of Science ®Google Scholar
• . Dahlof B, Devereux RB, Kjeldsen SE,; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003
   PubMed Web of Science ®Google Scholar
• . Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens. 2006;15(5):505–510
   PubMed Web of Science ®Google Scholar
• . Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117(25):3199–3205
   PubMed Web of Science ®Google Scholar
• . Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29(12):997–1005
   PubMed Web of Science ®Google Scholar
• . Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49(11):1157–1163
   PubMed Web of Science ®Google Scholar
• . Andersen K, Weinberger MH, Egan B,. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26(3):589–599
   PubMed Web of Science ®Google Scholar
• . Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens. 2007;21(10):780–787
   PubMed Web of Science ®Google Scholar
• . Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42(6):1137–1143
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8): 1012–1018
   PubMed Web of Science ®Google Scholar
• . Tekturna HCT (aliskiren and hydrochlorothiazide) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2008
   Google Scholar
• . Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672–678
   PubMed Web of Science ®Google Scholar
• . Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63(5):1874–1880
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456–1462
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR,; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D,; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia. 1996;39(5):587–593
   PubMed Web of Science ®Google Scholar
• . Persson F, Rossing P, Schjoedt KJ,. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73(12):1419–1425
   PubMed Web of Science ®Google Scholar
• . Chaturvedi N, Sjolie AK, Stephenson JM,. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28–31
   PubMed Web of Science ®Google Scholar
• . Chaturvedi N, Porta M, Klein R,. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394–1402
   PubMed Web of Science ®Google Scholar
• . Sjolie AK, Klein R, Porta M,. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372(9647):1385–1393
   PubMed Web of Science ®Google Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Mogensen CE, Neldam S, Tikkanen I,. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321(7274):1440–1444
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M,; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Uresin Y, Taylor AA, Kilo C,. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190–198
   PubMed Web of Science ®Google Scholar
• . Parving HH, Brenner BM, McMurray JJ,. ALiskiren Trial In Type 2 diabetes Using cardio-renal Disease Endpoints (ALTITUDE): Rationale and study design. J Am Soc Nephrol. 2007;18:95–2
   Google Scholar
• . Parving HH, Brenner BM, McMurray JJ,. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. Published ahead of print. 2009
   Google Scholar
• . American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(1):S80–S82
   PubMedGoogle Scholar
• . Weber MA, Julius S, Kjeldsen SE,. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051
   PubMed Web of Science ®Google Scholar
• . Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich). 2005;7(11):641–646
   PubMedGoogle Scholar
• . Flack JM. Epidemiology and unmet needs in hypertension. J Manag Care Pharm. 2007;13(8 suppl B):2–8
   PubMed Web of Science ®Google Scholar
• . Pool JL. Is it time to move to multidrug combinations? Am J Hypertens. 2003;16(11 pt 2):36S–40S
   PubMed Web of Science ®Google Scholar
• . Taylor AA. Combination drug treatment of hypertension: have we come full circle? Curr Cardiol Rep. 2004;6(6):421–426
   PubMedGoogle Scholar
• . Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159–2167
   PubMed Web of Science ®Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . de Boer IH, Kestenbaum B, Rue TC,. Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus. Arch Intern Med. 2008;168(17):1867–1873
   PubMedGoogle Scholar
• . Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383–393
   PubMed Web of Science ®Google Scholar
• . Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580–591
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO,; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298–304
   PubMed Web of Science ®Google Scholar
• . Bakris G, Hill M, Mancia G,. Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to action. J Hum Hypertens. 2008;22(1):63–70
   PubMed Web of Science ®Google Scholar
• . Barri YM. Hypertension and kidney disease: a deadly connection. Curr Hypertens Rep. 2008;10(1):39–45
   PubMed Web of Science ®Google Scholar
• . Rehberg PB. Studies on Kidney Function: The Rate of Filtration and Reabsorption in the Human Kidney. Biochem J. 1926;20(3):447–460
   PubMedGoogle Scholar
• . Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007;13( 3 suppl):S1–S9
   PubMed Web of Science ®Google Scholar
• . Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121(5):426–432
   PubMed Web of Science ®Google Scholar